Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Novacyt ( (FR:ALNOV) ) has issued an announcement.
Novacyt S.A. has provided a monthly update on its liquidity agreement with Invest Securities SA, detailing the purchase and sale of ordinary shares from December 1 to December 31, 2024. Invest Securities purchased 55,648 shares and sold 64,617 shares, with the company holding 70,592 shares in treasury as of December 31, 2024. The total number of ordinary shares stands at 70,626,248, which shareholders can use to assess changes in their interest in the company. This update impacts stakeholders by providing insights into Novacyt’s share liquidity and governance under the French Commercial Code, ensuring transparency and compliance in its financial operations.
More about Novacyt
Novacyt S.A. is an international molecular diagnostics company that provides a broad range of integrated technologies and services with a focus on genomic medicine. It develops, manufactures, and commercializes molecular assays and instrumentation for various sectors, including human health, animal health, and environmental. Novacyt operates through three business segments: Clinical, Instrumentation, and Research Use Only, offering products like in vitro diagnostic products, DNA sample preparation platforms, and pharmaceutical research services. Headquartered in France, Novacyt has offices in the UK, Singapore, the US, and Canada, and a commercial presence in over 65 countries.
Average Trading Volume: 471
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $44.04M
Find detailed analytics on ALNOV stock on TipRanks’ Stock Analysis page.
